A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABT-494 FOR INDUCTION AND MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS.

Intervention/treatment:
UPADACITINIB (ABT-494)
Medical condition:
ULCERATIVE COLITIS
Protocol code:
M14-234
Control number:
196541
Status:
Closed
Approved:
July 28, 2016
Date Completed:
Trial phase:
Phase 2, Phase 3
For more information:
ClinicalTrials.gov - NCT02819635
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
16 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Global Medical Services
Organization
AbbVie
Phone:
800-633-9110
Sponsor
ABBVIE CORPORATION

Locations

Alberta

Allen Whey Khye Lim Professional Corporation /ID# 211168
Edmonton, Alberta, T5R 1W2
Covenant Health /ID# 158930
Edmonton, Alberta, T6K 4B2
University of Alberta - Zeidler Ledcor Centre /ID# 151100
Edmonton, Alberta, T6G 2X8
University of Calgary /ID# 151821
Calgary, Alberta, T2N 4Z6

British Columbia

Okanagan Clinical Trials /ID# 153178
Kelowna, British Columbia, V1Y 1Z9
Percuro Clinical Research, Ltd /ID# 150367
Victoria, British Columbia, V8V 3M9

Ontario

Hamilton Health Sciences - McMaster University Medical Centre /ID# 150365
Hamilton, Ontario, L8S 4K1
Medicor Research Inc /ID# 151101
Greater Sudbury, Ontario, P3A 1W8
Ottawa Hospital Research Institute /ID# 151820
Ottawa, Ontario, K1H 8L6
Toronto Digestive Disease Asso /ID# 150363
Vaughan, Ontario, L4L 4Y7

Quebec

Centre Hospitalier de l'Universite de Montreal - CRCHUM /ID# 167169
Montreal, Quebec, H2X 0A9
CISSS de Chaudière-Appalaches, Hôpital Hotel-Dieu de Lévis /ID# 150361
Lévis, Quebec, G6V 3Z1
CISSS de la Monteregie /ID# 159215
Greenfield Park, Quebec, J4V 2H1
CIUSSS de l'Estrie - CHUS /ID# 150366
Sherbrooke, Quebec, J1G 2E8
Montreal General Hospital - McGill University Health Centre /ID# 170012
Montreal, Quebec, H3G 1A4
Recherche GCP Research /ID# 151822
Montreal, Quebec, H1M 1B1

Results

See the results from the trial NCT02819635. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?